Wealthcare Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Wealthcare Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-125	Closed	–	–	255
2020 Q1	$0	Hold	125	–	–	﹤0.01%	667
2019 Q4	$1K	Hold	125	–	–	﹤0.01%	664
2019 Q3	$1K	Hold	125	–	–	﹤0.01%	186
2019 Q2	$4K	Hold	125	–	–	﹤0.01%	165
2019 Q1	$3K	Hold	125	–	–	﹤0.01%	173
2018 Q4	$4K	Hold	125	–	–	﹤0.01%	167
2018 Q3	$10K	Hold	125	–	–	﹤0.01%	157
2018 Q2	$13K	Hold	125	–	–	﹤0.01%	145
2018 Q1	$16K	Hold	125	–	–	﹤0.01%	128
2017 Q4	$8K	Hold	125	–	–	﹤0.01%	144
2017 Q3	$7K	Hold	125	–	–	﹤0.01%	140
2017 Q2	$8K	Hold	125	–	–	﹤0.01%	129
2017 Q1	$10K	Hold	125	–	–	﹤0.01%	127
2016 Q4	$6K	Hold	125	–	–	﹤0.01%	140
2016 Q3	$9K	Hold	125	–	–	﹤0.01%	130
2016 Q2	$8K	Buy	125 +62	+98%	+$10.2K	﹤0.01%	133
2016 Q1	$14K	Hold	63	–	–	﹤0.01%	119
2015 Q4	$20K	Hold	63	–	–	﹤0.01%	115
2015 Q3	$19K	Hold	63	–	–	﹤0.01%	132
2015 Q2	$18K	Buy	+63	New	+$13.7K	﹤0.01%	158

Other funds holding ZVRA

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ISB

Iowa State Bank Urbandale, Iowa $592M AUM 21.15% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Wealthcare Capital Management's ZVRA Position: Q2 2020 in Review

Wealthcare Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2020, closing a stake of 125 shares.

Wealthcare Capital Management first reported a position in ZVRA in Q2 2015 and held it in 20 quarters. The position peaked at $20K in Q4 2015. 6 funds tracked by Wall St. Rank hold ZVRA as of Q2 2020.

Wealthcare Capital Management reported no remaining Zevra Therapeutics position as of Q2 2020 after selling out during the quarter.
Wealthcare Capital Management sold 125 Zevra Therapeutics shares in Q2 2020.
Wealthcare Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 20 quarters.
Wealthcare Capital Management's Zevra Therapeutics position peaked at $20K in Q4 2015.
6 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2020.

Based on Wealthcare Capital Management's 13F filing for Q2 2020, filed 29 Jul 2020.